Altered smallpox vaccine shows efficacy in advanced liver cancer

02/13/2013 | Bloomberg Businessweek

Advanced liver cancer patients who received high doses of a modified version of Jennerex's smallpox vaccine Pexa-Vec had a median survival of 14.1 months following injection compared with 6.7 months in those who had low-dose shots, researchers reported in Nature Medicine. Researchers also found 35% of patients treated with high doses were alive 18 months later.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN